Evaluation of a Noninvasive Diabetes Screening Device in Subjects at Risk for Diabetes

Completed

• Conditions: Diabetes
• Interventions: Device: SCOUT DS measurement

• Registration Number: NCT01080157
• Lead Sponsor: VeraLight, Inc.

Brief Summary

The purpose of this research study is to test the safety and effectiveness of the SCOUT DS in measuring the concentration of substances (advanced glycation endproducts) in the skin. These substances have been found to be in higher concentrations in people with diabetes and high blood sugar. The SCOUT DS is being developed to help doctors measure these substances in skin and possibly help doctors diagnose diabetes.

Detailed Description

The trial will be a prospective, multi-center, paired data, cohort screening trial. Up to 960 subjects will complete the study to determine the relative accuracy of SCOUT DS compared to the FPG and HbA1c tests in screening for abnormal glucose tolerance. All methods will be compared to the 2 hour value of the OGTT. An algorithm utilizes skin optical modeling as well as the spectral and blood assay data accumulated from the initial phase of the study to produce a risk score for abnormal glucose tolerance. This algorithm and the calculation of the score will be integrated into the SCOUT DS for prospective testing. The design requires three patient visits to the clinical site and up to a total of seven measurements on the SCOUT device.

Study Timeline

• Study Start: 2010-03
• Study First Submitted: 2010-03-01
• Study First Submitted QC: 2010-03-02
• Study First Posted: 2010-03-03
• Primary Completion: 2010-12
• Study Completion: 2010-12
• Status Verified: 2012-12
• Last Update Submitted: 2012-12-03
• Last Update Posted: 2012-12-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 509

Inclusion Criteria

1. Age greater than or equal to 45 years; OR

2. Age 18 to 44 years and a BMI > 25 kg/m² with one or more of the following risk factors:

   • Elevated waist circumference, > 35 inches for women and >40 inches for men
   • Habitually physically inactive (does not exercise regularly)
   • Has a first-degree relative with diabetes
   • African American, Latino, Native American, Asian American, Pacific Islander
   • Has delivered a baby weighing > 9 lb or diagnosed with gestational diabetes
   • Hypertension (≥130/≥ 85 mmHg) or being treated for hypertension
   • HDL cholesterol level < 35 mg/dL and/or a fasting triglyceride level ≥ 250 mg/dL or being treated for dyslipidemia with medication
   • Has been previously diagnosed with Polycystic Ovary Syndrome (PCOS)
   • Had impaired glucose tolerance or impaired fasting glucose on previous testing within the last 3 yrs
   • Conditions associated with insulin resistance such as acanthosis nigricans
   • History of vascular disease including heart attack, stroke, angina, coronary heart disease, atherosclerosis, congestive heart failure or peripheral arterial disease

Exclusion Criteria

• Prior participation in VL-2701
• Receiving investigational treatments in the past 14 days
• Psychosocial issues that interfere with an ability to follow study procedures
• Conditions that cause secondary diabetes including Cushing's syndrome, acromegaly, hemochromatosis, pancreatitis, or cystic fibrosis
• Diagnosed with any type of diabetes, including type 1 or 2
• Taking glucose lowering medications
• Known to be pregnant
• Receiving dialysis or having known renal compromise
• Scars, tattoos, rashes or other disruption/discoloration on the left volar forearm.
• Recent (within past month) or current oral steroid therapy or topical steroids applied to the left forearm; inhaled steroid therapy is not excluded Current chemotherapy, or chemotherapy within the past 12 months
• Receiving medications that fluoresce
• Known to have, or at risk for, photosensitivity reactions ( e.g., sensitive to ultraviolet light, or taking medication known to cause photosensitivity)
• Prior bariatric surgery

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Volunteers 18+, at risk for diabetes	SCOUT DS measurement	-

Primary Outcome Measures

Name	Time	Method
Validation of SCOUT DS algorithm, ROC performance equivalency to FPG and A1c for detection of abnormal glucose tolerance.	Outcome measure is determined 2-3 months after completion of Visit 3	The relative true positive and relative true negative fractions between the SCOUT DS and FPG tests for detecting abnormal glucose tolerance (2 hr OGTT value ≥ 140 mg/dL)

Secondary Outcome Measures

Name	Time	Method
Receiver operator characteristic area under the curve, sensitivity, specificity, and postive & negative predictive values of the SCOUT DS, FPG, and A1C tests for detection of abnormal glucose tolerance, and the intra- & inter-day SCOUT DS test	Outcome measure is determined 2-3 months after completion of Visit 3

Trial Locations

Locations (12)

Radiant Research, Inc. - Cincinnati; 🇺🇸 Cincinnati, Ohio, United States

Radiant Research, Inc. - Chicago; 🇺🇸 Chicago, Illinois, United States

Dynamed Clinical Research, LP; 🇺🇸 Houston, Texas, United States

Accelovance - San Diego, CA; 🇺🇸 San Diego, California, United States

Accelovance - Huntsville; 🇺🇸 Huntsville, Alabama, United States

Radiant Research, Inc. - Minneapolis; 🇺🇸 Minneapolis, Minnesota, United States

Accelovance - Rockville, MD; 🇺🇸 Rockville, Maryland, United States

Lovelace Scientific Resources, Inc.; 🇺🇸 Albuquerque, New Mexico, United States

Juno Research, LLC; 🇺🇸 Houston, Texas, United States

Radiant Research, Inc. - Kansas City; 🇺🇸 Kansas City, Kansas, United States

Accelovance - Peoria, IL; 🇺🇸 Peoria, Illinois, United States

Radiant Research, Inc. - San Antonio; 🇺🇸 San Antonio, Texas, United States